NLRP3 and neoplasm: Addition of the NLRP3 agonist significantly improved tumor control of 12Gy and 5Gy XRT in both 344SQ-P (P < 0.0001 vs. XRT, Fig. 1d; P = 0.0015 vs. XRT, supplementary figure S1e) and 344SQ-R models (all P < 0.0001 vs. XRT, Fig. 1e, supplementary figure S1f).